EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining a CMV viral load threshold for pre‐emptive therapy in paediatric haematopoietic stem cell transplant recipients

Amedine Duret iD, Oscar Charles, Ben K Margetts, John Booth, Julianne R Brown, Timothy Best, Sneha Fernandes, Persis Amrolia, Robert Chiesa, Juliana Silva iD, Austen Worth, Joseph F Standing und 4 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Amedine Duret und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Infectious Diseases, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Viral Load, Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Imperial Biomedical Research Centre, UCLH Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection is a significant complication in paediatric haematopoietic stem cell transplant (HSCT), with substantial morbidity and mortality. While pre‐emptive treatment guided by CMV viral load thresholds helps prevent end‐organ disease, paediatric protocols have largely been extrapolated from adult populations without robust validation. This prospective interventional study aimed to determine an optimal viral load threshold for initiating pre‐emptive CMV therapy in paediatric HSCT patients and test the impact of this threshold in real‐world practice. Initially, 219 paediatric HSCT patients from 2009 to 2016 were considered, with weekly CMV quantitative polymerase chain reaction (qPCR) monitoring and treatment initiation at 2500 IU/mL. A mathematical model was developed to analyse CMV kinetics, morbidity and mortality, suggesting a threshold of 1000 IU/mL would be most suitable to prevent adverse outcomes. Subsequently, the new treatment threshold was implemented, and outcomes were then compared with a second cohort of 344 patients treated under the new guidelines from 2017 to 2021. There were significant reductions in CMV viral loads, CMV‐associated end‐organ disease (27/117, 23.1% vs. 4/98, 4.1%) and mortality (36/117, 30.8% vs. 19/98, 19.4%). These findings support a new evidence‐based viral load threshold of 1000 IU/mL or less for pre‐emptive treatment in paediatric HSCT recipients to optimise clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral LoadHematopoietic Stem Cell TransplantationCytomegalovirus InfectionsCytomegalovirusAntiviral AgentsHumansChildMaleFemaleAdolescentChild, PreschoolProspective StudiesInfant

Stichwörter der Autor:innen

BMT paedHSC transplantationcytomegalovirusvirology

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Paediatric Infectious Diseases, Imperial College London, London, UK.
  • Infection, Immunity, and Inflammation, Institute of Child Health, University College London, London, UK.
  • Centre for Computation, Mathematics, & Physics in the Life Sciences and Experimental Biology, University College London, London, UK.
  • Digital Research Environment, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Microbiology, Virology and Infection Prevention and Control, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Department of Blood and Marrow Transplantation, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

ORCID-Profile: Amedine Duret, Juliana Silva

Förderung

  • NIHR Imperial Biomedical Research Centre
  • UCLH Biomedical Research Centre

Zitieren

APA

Duret, A., Charles, O., Margetts, B. K., Booth, J., Brown, J. R., Best, T., Fernandes, S., Amrolia, P., Chiesa, R., Silva, J., Worth, A., Standing, J. F., Rao, K., Whittaker, E., Gil, E., & Breuer, J. (2025). Defining a CMV viral load threshold for pre‐emptive therapy in paediatric haematopoietic stem cell transplant recipients. British Journal of Haematology. https://doi.org/10.1111/bjh.20254

Vancouver

Duret A, Charles O, Margetts BK, Booth J, Brown JR, Best T, et al. Defining a CMV viral load threshold for pre‐emptive therapy in paediatric haematopoietic stem cell transplant recipients. British Journal of Haematology. 2025. doi:10.1111/bjh.20254

BibTeX
@article{Duret2025,
  author = {Duret, Amedine and Charles, Oscar and Margetts, Ben K and Booth, John and Brown, Julianne R and Best, Timothy and Fernandes, Sneha and Amrolia, Persis and Chiesa, Robert and Silva, Juliana and Worth, Austen and Standing, Joseph F and Rao, Kanchan and Whittaker, Elizabeth and Gil, Eliza and Breuer, Judith},
  title = {Defining a CMV viral load threshold for pre‐emptive therapy in paediatric haematopoietic stem cell transplant recipients},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20254}
}
Kostenlos starten →